title: Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
  
  
  RESULTS
  This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000).
  
  
  CONCLUSIONS
  As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.
authors.affiliation: Gil Hospital. Gachon University of Medicine and Science, Incheon, Republic of Korea.
authors.forename: Woong Chol
authors.initials: WC
authors.lastname: Kang
authors.forename: Taehoon
authors.initials: T
authors.lastname: Ahn
authors.forename: Kyounghoon
authors.initials: K
authors.lastname: Lee
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Han
authors.forename: Eak Kyun
authors.initials: EK
authors.lastname: Shin
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Yoon
authors.forename: Jong Sun
authors.initials: JS
authors.lastname: Park
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Seung Woon
authors.initials: SW
authors.lastname: Rha
authors.forename: Seok Kyu
authors.initials: SK
authors.lastname: Oh
authors.forename: Doo Il
authors.initials: DI
authors.lastname: Kim
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Jae Woong
authors.initials: JW
authors.lastname: Choi
authors.forename: Byung Ok
authors.initials: BO
authors.lastname: Kim
mesh_terms: D000368:Aged; D000792:Angiography; D017130:Angioplasty / Q000295:instrumentation; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D056910:Republic of Korea; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C489443:zotarolimus; D017239:Paclitaxel; D020123:Sirolimus